文献速递肝病

美国2型糖尿病患者中高危代谢功能障碍相关脂肪性肝炎患病率的前瞻性研究

A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.
PubMed 文献 · Aliment Pharmacol Ther · 2024-04-08

这项前瞻性研究纳入美国南加州2016至2023年招募的530例≥50岁2型糖尿病成人,MASLD定义为MRI质子密度脂肪分数≥5%且至少一项代谢危险因素。MASLD、高危MASH和肝硬化患病率分别为69.6%、13.6%和6.8%;合并肥胖者分别为77.8%、15.9%和9.0%,高于非肥胖者。

要点

  • 2型糖尿病成人中MASLD患病率69.6%,高危MASH为13.6%,肝硬化为6.8%。
  • 2型糖尿病合并肥胖者高危MASH患病率15.9%,肝硬化9.0%。
  • 约14%的2型糖尿病患者可能是MASH相关纤维化特异性药物治疗的候选者。

核心结论

  • 在≥50岁2型糖尿病成人中,MASLD、高危MASH和肝硬化的患病率均较高,构成显著的肝脏相关疾病和死亡风险。
  • 约14%的2型糖尿病患者可能是MASH相关纤维化特异性药物治疗的候选者。

研究设计与样本

  • 前瞻性研究,2016至2023年从美国南加州初级保健和内分泌科诊所招募≥50岁2型糖尿病成人,共纳入530例。
  • MASLD定义为磁共振成像质子密度脂肪分数≥5%且至少一项代谢危险因素,且无其他慢性肝病或肝脂肪变性继发原因。

主要发现

  • 2型糖尿病患者中MASLD、高危MASH和肝硬化患病率分别为69.6%、13.6%和6.8%。
  • 2型糖尿病合并肥胖者中MASLD、高危MASH和肝硬化患病率分别为77.8%、15.9%和9.0%。
  • 2型糖尿病合并肥胖者上述患病率高于非肥胖者,MASLD比较p < 0.0001,高危MASH比较p = 0.0543,肝硬化比较p = 0.0128。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on the prevalence and treatment of at-risk metabolic dysfunction-associated steatohepatitis (MASH) among patients with type 2 diabetes (T2DM) in the United States. AIM: To estimate the prevalence of at-risk MASH in a prospectively recruited cohort of adults with T2DM using new nomenclature endorsed by multiple societies. METHODS: This prospective study enrolled adults aged ≥50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined by an magnetic resonance imaging proton density fat fraction ≥5% and at least one metabolic risk factor without any other chronic liver disease or secondary cause for hepatic steatosis. RESULTS: We included 530 adult patients with T2DM. The mean (±SD) age and body mass index (BMI) were 64.4 (±8.1) years and 31.5 (±6.1) kg/m2, respectively. Among patients with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis was 69.6%, 13.6% and 6.8%, respectively. Among patients with co-existing T2DM and obesity, the prevalence of MASLD, at-risk MASH and cirrhosis was 77.8%, 15.9% and 9.0%, respectively, and was higher than in participants without obesity (p < 0.0001, 0.0543 and 0.0128, respectively). CONCLUSION: Among adults aged ≥50 years with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis is high, posing a significant risk for liver-related morbidity and mortality. Approximately 14% of patients with T2DM may be candidates for pharmacologic therapies specific to MASH-related fibrosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mittal N, Siddiqi H, Madamba E, et al. A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States. Aliment Pharmacol Ther. 2024. PMID: 38586922. doi:10.1111/apt.17997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。